BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 18952300)

  • 1. Evaluation of vaccination strategies against infection with feline immunodeficiency virus (FIV) based on recombinant viral vectors expressing FIV Rev and OrfA.
    Huisman W; Schrauwen EJ; Tijhaar E; Süzer Y; Pas SD; van Amerongen G; Sutter G; Rimmelzwaan GF; Osterhaus AD
    Vet Immunol Immunopathol; 2008 Dec; 126(3-4):332-8. PubMed ID: 18952300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Should accessory proteins be structural components of lentiviral vaccines? Lessons learned from the accessory ORF-A protein of FIV.
    Pistello M
    Vet Immunol Immunopathol; 2008 May; 123(1-2):144-9. PubMed ID: 18304653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of ISCOM-adjuvanted subunit vaccines containing recombinant feline immunodeficiency virus Rev, OrfA and envelope protein in cats.
    Huisman W; Schrauwen EJ; Pas SD; van Amerongen G; Rimmelzwaan GF; Osterhaus AD
    Vaccine; 2008 May; 26(21):2553-61. PubMed ID: 18430494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prime-boost vaccination using DNA and whole inactivated virus vaccines provides limited protection against virulent feline immunodeficiency virus.
    Dunham SP; Bruce J; Klein D; Flynn JN; Golder MC; MacDonald S; Jarrett O; Neil JC
    Vaccine; 2006 Nov; 24(49-50):7095-108. PubMed ID: 17049683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pre-existing immunity to pathogenic Listeria monocytogenes does not prevent induction of immune responses to feline immunodeficiency virus by a novel recombinant Listeria monocytogenes vaccine.
    Stevens R; Lavoy A; Nordone S; Burkhard M; Dean GA
    Vaccine; 2005 Feb; 23(12):1479-90. PubMed ID: 15670884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccination of cats experimentally infected with feline immunodeficiency virus, using a recombinant feline leukemia virus vaccine.
    Lehmann R; Franchini M; Aubert A; Wolfensberger C; Cronier J; Lutz H
    J Am Vet Med Assoc; 1991 Nov; 199(10):1446-52. PubMed ID: 1666101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gag-specific immune enhancement of lentiviral infection after vaccination with an adenoviral vector in an animal model of AIDS.
    Klonjkowski B; Klein D; Galea S; Gavard F; Monteil M; Duarte L; Fournier A; Sayon S; Górna K; Ertl R; Cordonnier N; Sonigo P; Eloit M; Richardson J
    Vaccine; 2009 Feb; 27(6):928-39. PubMed ID: 19070641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual-subtype vaccine (Fel-O-Vax FIV) protects cats against contact challenge with heterologous subtype B FIV infected cats.
    Kusuhara H; Hohdatsu T; Okumura M; Sato K; Suzuki Y; Motokawa K; Gemma T; Watanabe R; Huang C; Arai S; Koyama H
    Vet Microbiol; 2005 Jul; 108(3-4):155-65. PubMed ID: 15899558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective immunity against feline immunodeficiency virus induced by inoculation with vif-deleted proviral DNA.
    Lockridge KM; Chien M; Dean GA; Stefano Cole K; Montelaro RC; Luciw PA; Sparger EE
    Virology; 2000 Jul; 273(1):67-79. PubMed ID: 10891409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved protection against simian immunodeficiency virus mucosal challenge in macaques primed with a DNA vaccine and boosted with the recombinant modified vaccinia virus Ankara and recombinant Semliki Forest virus.
    Martinon F; Brochard P; Ripaux M; Delache B; Aurégan G; Vaslin B; Le Grand R
    Vaccine; 2008 Jan; 26(4):532-45. PubMed ID: 18093703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The development of a vaccine against feline immunodeficiency virus.
    Hosie MJ
    Br Vet J; 1994; 150(1):25-39. PubMed ID: 8025833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lessons from the cat: development of vaccines against lentiviruses.
    Dunham SP
    Vet Immunol Immunopathol; 2006 Jul; 112(1-2):67-77. PubMed ID: 16678276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peptide mapping of feline immunodeficiency virus by IFN-gamma ELISPOT.
    Dean GA; LaVoy A; Burkhard MJ
    Vet Immunol Immunopathol; 2004 Jul; 100(1-2):49-59. PubMed ID: 15182995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy evaluation of prime-boost protocol: canarypoxvirus-based feline immunodeficiency virus (FIV) vaccine and inactivated FIV-infected cell vaccine against heterologous FIV challenge in cats.
    Tellier MC; Pu R; Pollock D; Vitsky A; Tartaglia J; Paoletti E; Yamamoto JK
    AIDS; 1998 Jan; 12(1):11-8. PubMed ID: 9456250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Vaccination of cats against infection with feline leukemia virus (FeLV): first recombinant vaccine and the effect of a pre-existing infection with feline immunodeficiency virus (FIV)].
    Hofmann-Lehmann R; Aubert A; Wolfensberger C; Cronier J; Lutz H
    Schweiz Arch Tierheilkd; 1994; 136(10):340-51. PubMed ID: 7801087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Partial protection by vaccination with recombinant feline immunodeficiency virus surface glycoproteins.
    Leutenegger CM; Hofmann-Lehmann R; Holznagel E; Cuisinier AM; Wolfensberger C; Duquesne V; Cronier J; Allenspach K; Aubert A; Ossent P; Lutz H
    AIDS Res Hum Retroviruses; 1998 Feb; 14(3):275-83. PubMed ID: 9491919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual-subtype FIV vaccine (Fel-O-Vax FIV) protection against a heterologous subtype B FIV isolate.
    Pu R; Coleman J; Coisman J; Sato E; Tanabe T; Arai M; Yamamoto JK
    J Feline Med Surg; 2005 Feb; 7(1):65-70. PubMed ID: 15686976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MHC-restricted protection of cats against FIV infection by adoptive transfer of immune cells from FIV-vaccinated donors.
    Pu R; Omori M; Okada S; Rine SL; Lewis BA; Lipton E; Yamamoto JK
    Cell Immunol; 1999 Nov; 198(1):30-43. PubMed ID: 10612649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccination against the feline immunodeficiency virus: the road not taken.
    Lecollinet S; Richardson J
    Comp Immunol Microbiol Infect Dis; 2008 Mar; 31(2-3):167-90. PubMed ID: 17706778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Env-specific CTL predominate in cats protected from feline immunodeficiency virus infection by vaccination.
    Flynn JN; Keating P; Hosie MJ; Mackett M; Stephens EB; Beatty JA; Neil JC; Jarrett O
    J Immunol; 1996 Oct; 157(8):3658-65. PubMed ID: 8871667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.